BioNTech SE - ADR vs Lemonade Inc — how do they compare? BioNTech SE - ADR trades at $93.17 (market cap $23.31B), while Lemonade Inc trades at $51.29 (market cap $4.09B). The key difference: BioNTech SE - ADR is far larger — about 5.7× Lemonade Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| BNTX | LMND | |
|---|---|---|
Market Cap | $23.31B | $4.09B |
Sector | Health | Financials |
52-Week High | $119.34 | $96.57 |
52-Week Low | $83.89 | $47.38 |
Enterprise Value | $6.60B | $3.95B |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Lemonade (LMND) trades at $51.21, down 2.79% in the past 24 hours, with a bearish technical signal indicated by moving averages and ADX. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 79% year-over-year, but remains unprofitable with a net income margin of -14.19%. Recent news highlights a CFO transition and expansion into new states, while the stock faces volatility amid mixed analyst sentiment.
The outlook for LMND hinges on achieving profitability, guided for Q4 2026, but high valuation (P/S of 4.1) and persistent losses pose risks. Opportunities include AI-driven growth and market expansion, yet investors face execution risks and competitive pressures in the insurance sector.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →